The company leverages proprietary ADC platform technology with deep oncology expertise to develop highly targeted cancer therapies. ADC Therapeutics operates globally with R&D in London, clinical and commercial operations in New Jersey, and manufacturing/CMC capabilities in the San Francisco Bay Area, positioning itself as a leader in the specialized ADC therapeutic space.
Cyborg Score Rationale
ADC Therapeutics has achieved regulatory approval and commercialization of ZYNLONTA, demonstrating scientific validation and market traction. However, the company faces challenges including significant operating losses, declining market capitalization, and revenue pressures that create execution risk despite a promising pipeline.
Top Insights
Flagship product ZYNLONTA holds FDA accelerated approval for DLBCL with ongoing Phase 3 expansion (LOTIS-5) into earlier treatment lines and additional lymphoma indications
Market capitalization declined to $518M (Feb 2026) from IPO price of $17/share (May 2020), reflecting biotech sector volatility and execution challenges
Pipeline includes ADCT-602 for acute lymphoblastic leukemia and multiple solid tumor candidates (Claudin-6, PSMA, NaPi2b, ASCT2) addressing distinct oncology segments
Global operations and regulatory approvals in US, EU, and China provide geographic diversification and international revenue potential beyond US market
Named Competitors
Targeted Cancer Therapies — Precision oncology using photodynamic therapy and other targeted approaches
ADC Development Platform — Pioneer in antibody-drug conjugates for hematologic and solid tumors
Targeted Immuno-Oncology — Various approaches to hematologic malignancies and solid tumor treatment
Recent Developments
(Feb 2026) Stock price at $4.18 with market cap of $518M, reflecting recent market positioning
(2023) Reported $185.4M revenue and $246.3M net loss; $272.6M cash position supports pipeline advancement
(Ongoing) LOTIS-5 Phase 3 trial expanding ZYNLONTA into earlier DLBCL lines and indolent lymphomas including follicular and marginal zone lymphoma
Open the full interactive ADC Therapeutics SA report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.